Home
Storia in 1 fonti
Zydus Lifesciences acquires US pharma firm Assertio for $166 million
In a bold move that positions Zydus at the forefront of the U.S. specialty oncology market, the Indian drug manufacturer has secured a $166.40 million deal to acquire Assertio Holdings. The purchase includes Assertios essential cancer treatment, Rolvedon, and offers Zydus a rich commercial network to elevate its oncology initiatives.
Raccontata da
economictimes.indiatimes.com
Timeline cronologica
- ·
Zydus Lifesciences acquires US pharma firm Assertio for $166 million
In a bold move that positions Zydus at the forefront of the U.S. specialty oncology market, the Indian drug manufacturer has secured a $166.40 million deal to acquire Assertio…
- ·
Zydus Lifesciences shares jump 6% on buyback buzz; co announces $166 mn Assertio acquisition
Zydus Lifesciences shares witnessed a spike on Thursday after the company said its board will meet on May 19 to consider a share buyback. The stock also gained momentum as Zydus…